首页> 美国卫生研究院文献>Molecules >Toll-Like Receptor-Mediated Recognition of Nucleic Acid Nanoparticles (NANPs) in Human Primary Blood Cells
【2h】

Toll-Like Receptor-Mediated Recognition of Nucleic Acid Nanoparticles (NANPs) in Human Primary Blood Cells

机译:人原代细胞中类似的受体介导的核酸纳米颗粒(NANPs)的识别。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Infusion reactions (IRs) create a translational hurdle for many novel therapeutics, including those utilizing nanotechnology. Nucleic acid nanoparticles (NANPs) are a novel class of therapeutics prepared by rational design of relatively short oligonucleotides to self-assemble into various programmable geometric shapes. While cytokine storm, a common type of IR, has halted clinical development of several therapeutic oligonucleotides, NANP technologies hold tremendous potential to bring these reactions under control by tuning the particle’s physicochemical properties to the desired type and magnitude of the immune response. Recently, we reported the very first comprehensive study of the structure–activity relationship between NANPs’ shape, size, composition, and their immunorecognition in human cells, and identified the phagolysosomal pathway as the major route for the NANPs’ uptake and subsequent immunostimulation. Here, we explore the molecular mechanism of NANPs’ recognition by primary immune cells, and particularly the contributing role of the Toll-like receptors. Our current study expands the understanding of the immune recognition of engineered nucleic acid-based therapeutics and contributes to the improvement of the nanomedicine safety profile.
机译:输液反应(IR)为许多新型疗法(包括利用纳米技术的疗法)带来了转化障碍。核酸纳米颗粒(NANPs)是一类新颖的疗法,它是通过合理设计相对较短的寡核苷酸以自组装成各种可编程的几何形状而制备的。细胞因子风暴是一种常见的IR,已经停止了几种治疗性寡核苷酸的临床开发,而NANP技术则具有巨大的潜力,可以通过将粒子的理化性质调节至所需的免疫反应类型和强度,来控制这些反应。最近,我们报道了关于人类细胞中NANPs的形状,大小,组成及其免疫识别之间的结构-活性关系的首次全面研究,并确定了吞噬酶体途径是NANPs摄取和随后的免疫刺激的主要途径。在这里,我们探讨了原代免疫细胞识别NANP的分子机制,特别是Toll样受体的贡献作用。我们当前的研究扩大了对基于核酸的工程疗法的免疫识别的理解,并有助于改善纳米药物的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号